Parallax Volatility Advisers’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-63,249
| Closed | -$11.6M | – | 1470 |
|
|
2025
Q4 | $11.6M | Buy |
63,249
+14,936
| +31% | +$2.62M | 0.02% | 419 |
|
|
2025
Q3 | $7.41M | Buy |
48,313
+17,520
| +57% | +$2.65M | 0.01% | 567 |
|
|
2025
Q2 | $4.3M | Buy |
30,793
+30,791
| +1,539,550% | +$4.32M | 0.01% | 662 |
|
|
2025
Q1 | $221 | Sell |
2
-22,728
| -100% | -$3.29M | ﹤0.01% | 1488 |
|
|
2024
Q4 | $2.98M | Buy |
+22,730
| New | +$3.18M | 0.01% | 1018 |
|
|
2023
Q3 | – | Sell |
-6,719
| Closed | -$918K | – | 2282 |
|
|
2023
Q2 | $962K | Buy |
6,719
+6,689
| +22,297% | +$984K | ﹤0.01% | 1415 |
|
|
2023
Q1 | $4.17K | Hold |
30
| – | – | ﹤0.01% | 2503 |
|
|
2022
Q4 | $4.07K | Sell |
30
-34,475
| -100% | -$4.32M | ﹤0.01% | 2652 |
|
|
2022
Q3 | $3.78M | Buy |
+34,505
| New | +$4.38M | 0.01% | 1133 |
|
|
2020
Q4 | – | Sell |
-10,268
| Closed | -$1.13M | – | 2396 |
|
|
2020
Q3 | $1.13M | Buy |
10,268
+4,568
| +80% | +$508K | ﹤0.01% | 1942 |
|
|
2020
Q2 | $603K | Buy |
5,700
+2,292
| +67% | +$237K | ﹤0.01% | 1910 |
|
|
2020
Q1 | $304K | Buy |
3,408
+35
| +1% | +$3.29K | ﹤0.01% | 1881 |
|
|
2019
Q4 | $336K | Sell |
3,373
-288
| -8% | -$27.1K | ﹤0.01% | 1871 |
|
|
2019
Q3 | $326K | Buy |
3,661
+2,936
| +405% | +$255K | ﹤0.01% | 1731 |
|
|
2019
Q2 | $60K | Sell |
725
-2,920
| -80% | -$229K | ﹤0.01% | 1938 |
|
|
2019
Q1 | $295K | Buy |
3,645
+53
| +1% | +$4.18K | ﹤0.01% | 1722 |
|
|
2018
Q4 | $273K | Sell |
3,592
-11,924
| -77% | -$931K | ﹤0.01% | 1668 |
|
|
2018
Q3 | $1.23M | Buy |
15,516
+4,906
| +46% | +$371K | ﹤0.01% | 1195 |
|
|
2018
Q2 | $745K | Buy |
+10,610
| New | +$763K | ﹤0.01% | 1170 |
|
|
2017
Q3 | – | Sell |
-24,064
| Closed | -$1.52M | – | 2082 |
|
|
2017
Q2 | $1.64M | Buy |
+24,064
| New | +$1.57M | ﹤0.01% | 902 |
|
|
2017
Q1 | – | Sell |
-101,486
| Closed | -$5.91M | – | 3535 |
|
|
2016
Q4 | $5.54M | Buy |
+101,486
| New | +$5.76M | 0.01% | 611 |
|
|
2016
Q3 | – | Sell |
-50,580
| Closed | -$3.31M | – | 2858 |
|
|
2016
Q2 | $3.05M | Buy |
+50,580
| New | +$2.94M | 0.01% | 782 |
|
|
2016
Q1 | – | Sell |
-6,689
| Closed | -$402K | – | 2493 |
|
|
2015
Q4 | $454K | Buy |
+6,689
| New | +$439K | ﹤0.01% | 1587 |
|
Other funds holding AZN
IA
Parallax Volatility Advisers's AZN Position: Q1 2026 in Review
Parallax Volatility Advisers sold out of AstraZeneca (AZN) in Q1 2026, closing a stake of 63,249 shares — an estimated $11.6M sold.
Parallax Volatility Advisers first reported a position in AZN in Q4 2015 and held it in 23 quarters. The position peaked at $11.6M in Q4 2025. 1,383 funds tracked by Wall St. Rank hold AZN as of Q1 2026.
- Parallax Volatility Advisers reported no remaining AstraZeneca position as of Q1 2026 after selling out during the quarter.
- Parallax Volatility Advisers sold 63,249 AstraZeneca shares in Q1 2026, an estimated $11.6M.
- Parallax Volatility Advisers first reported a position in AstraZeneca in Q4 2015 and held it in 23 quarters.
- Parallax Volatility Advisers's AstraZeneca position peaked at $11.6M in Q4 2025.
- 1,383 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.
Based on Parallax Volatility Advisers's 13F filing for Q1 2026, filed 15 May 2026.